Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$2.45
-0.13 (-5.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $284.1M · quality 83.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
62/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
6.0x
↓EV/EBITDA
4.2x
↓ROE
11.8%
↑Gross Margin
84.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
+16.0%
FCF margin
33.4%
FCF / Net income
1.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $901.9M · net income $198.9M · FCF $300.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $901.9M | $901.9M | $881.2M | $841.5M | $841.6M |
| Net Income | $198.9M | $198.9M | $184.3M | $148.2M | $193.6M |
| EBITDA | $294.2M | $294.2M | $236.3M | $226.4M | $231.4M |
| EPS | 0.35 | 0.35 | 0.33 | 0.26 | 0.35 |
| Gross Margin | 84.0% | 84.0% | 77.8% | 69.4% | 77.0% |
| Operating Margin | 23.8% | 23.8% | 20.8% | 19.0% | 18.3% |
| Net Margin | 22.1% | 22.1% | 20.9% | 17.6% | 23.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.04 | 0.05 | 0.00 |
| Current Ratio | 1.30 | 1.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $300.8M | $300.8M | $208.6M | $284.1M | $192.7M |
| Returns | |||||
| ROE | 11.8% | 11.8% | 11.3% | 10.0% | 12.0% |
| Valuation | |||||
| P/E | 5.98 | 5.98 | 4.17 | 6.47 | 2.63 |
| EV/EBITDA | 4.18 | 4.18 | 2.56 | 3.03 | 1.71 |
| P/B | 0.81 | 0.81 | 0.47 | 0.65 | 0.32 |
| Growth & Yield | |||||
| Revenue Growth | 2.4% | 2.4% | 4.7% | -0.0% | — |
| EPS Growth | 7.9% | 7.9% | 24.3% | -23.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-15.1%
EPS terminal req.
$0.22
Spread vs growth
23.0%
5Y implied EPS CAGR
-5.8%
EPS terminal req.
$0.26
Spread vs growth
13.8%
10Y implied EPS CAGR
1.8%
EPS terminal req.
$0.42
Spread vs growth
6.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.4%
Start / end P/E
6.7x → 6.9x
EPS bridge
0.33 → 0.35
Residual
+0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.